Compounds > imiquimod
Page last updated: 2024-08-24

imiquimod and Cancer, Second Primary

imiquimod has been researched along with Cancer, Second Primary in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Arimura, A; Kanekura, T; Kirishima, M; Tanimoto, A1
Kim, JYS; Kozlow, JH; Mittal, B; Moyer, J; Olencki, T; Rodgers, P1
Guevara-Gutiérrez, E; Hernández-Torres, M; Ledesma, GS; Ruiz-González, JF; Tlacuilo-Parra, A1
Goh, MS1
Germain, M; Skelton, H; Smith, KJ1

Other Studies

5 other study(ies) available for imiquimod and Cancer, Second Primary

ArticleYear
Eruptive squamous cell carcinoma in a patient treated with concomitant pembrolizumab and imiquimod.
    The Journal of dermatology, 2019, Volume: 46, Issue:12

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Carcinoma, Squamous Cell; Female; Humans; Imiquimod; Lung Neoplasms; Neoplasms, Second Primary; Skin Neoplasms; Urinary Bladder Neoplasms

2019
Guidelines of care for the management of basal cell carcinoma.
    Journal of the American Academy of Dermatology, 2018, Volume: 78, Issue:3

    Topics: Administration, Cutaneous; Aminoquinolines; Anilides; Antineoplastic Agents; Carcinoma, Basal Cell; Dermatologic Surgical Procedures; Early Detection of Cancer; Humans; Imiquimod; Neoplasm Grading; Neoplasm Staging; Neoplasms, Second Primary; Photochemotherapy; Photosensitizing Agents; Pyridines; Radiotherapy; Skin Neoplasms; United States

2018
[Riesgo de recurrencia y de nuevas neoplasias cutáneas malignas en sujetos mexicanos con carcinoma basocelular].
    Cirugia y cirujanos, 2018, Volume: 86, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cryosurgery; Electrocoagulation; Female; Humans; Imiquimod; Male; Margins of Excision; Middle Aged; Mohs Surgery; Neoplasms, Second Primary; Recurrence; Retrospective Studies; Risk; Skin Neoplasms; Young Adult

2018
Invasive squamous cell carcinoma after treatment of carcinoma in situ with 5% imiquimod cream.
    The Australasian journal of dermatology, 2006, Volume: 47, Issue:3

    Topics: Administration, Topical; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Squamous Cell; Disease Progression; Head and Neck Neoplasms; Humans; Imiquimod; Leg; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Second Primary; Scalp; Skin Neoplasms; Treatment Outcome

2006
Bowen's disease (squamous cell carcinoma in situ) in immunosuppressed patients treated with imiquimod 5% cream and a cox inhibitor, sulindac: potential applications for this combination of immunotherapy.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2001, Volume: 27, Issue:2

    Topics: Adjuvants, Immunologic; Administration, Topical; Aged; Aminoquinolines; Antineoplastic Agents; Bowen's Disease; Carcinoma in Situ; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Female; Humans; Imiquimod; Immunosuppression Therapy; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasms, Second Primary; Ointments; Skin Neoplasms; Sulindac

2001